By Matt McCallMay 01, 2019
That was fast!
Just two weeks ago, I emailed you a series of articles explaining how you can get rich from a rare market anomaly.
I showed you a chart that is first and foremost on the minds of many marijuana CEOs.
I told you about a stock that climbed nearly 10,000% in two-and-a-half years. And another that soared 2,800%+ also in two-and-a-half years.
I introduced you to what I call my Jumper Stock System. This system identifies and exploits one of the biggest but often overlooked catalysts in the marijuana market.
I hope you paid attention, because just five trading days after the final article, one of the stocks my system identified made the announcement we expected. We’re already seeing the beginnings of what I expect will ultimately be a sky high trajectory.
Jumper Stocks are just one big opportunity we’re following in Early Stage Investor. This is my venture-capital like small-cap stock service, and in fairness to my subscribers, I normally can’t give away information.
I’m making an exception today because I want you to understand how big of an opportunity Jumper Stocks are… and how we’re just at the beginning of this trend that should last a few years.
In a nutshell, Jumper Stocks are those that trade on minor stock exchanges and then uplist to a major exchange like the New York Stock Exchange (NYSE), NASDAQ, or the Toronto Stock Exchange (TSX) in Canada. Making this leap transforms the stock and can make investors rich. Jumping to a major exchange provides instant credibility, opens the stock up to big institutional money, and results in more analyst coverage.
The company I want to make sure you know about today is Organigram (OGRMF). On Friday, it announced that is has filed the application to jump from the OTC (over-the-counter) markets to trade with the big boys on the NASDAQ.
Since Friday’s announcement, the shares are already up 17% on higher-than-average volume.
This is only the beginning.
We identified Organigram in part because I expected it to jump, but I need to see much more than just that possibility to recommend a stock. This company fits the bill.
Organigram is a licensed producer of medical and recreational cannabis in Canada. It’s in great position as one of only three companies with supply agreements in all 10 provinces. And thanks to its dominant footprint in Canada, it has also been able to expand internationally.
When you think about the biggest names in marijuana, your mind automatically goes to Canopy Growth (CGC), Aurora Cannabis (ACB), and Tilray (TLRY). That’s fair – they are the three largest companies by market cap. But even though you don’t hear as much about it, Organigram isn’t far behind.
In fact, in the most recent quarter Organigram sold nearly 5,000 kilograms (kg) of cannabis across Canada. The only company to outsell Organigram happens to be the biggest marijuana company on earth, Canopy, which sold about 8,700 kg. Aphria (APHA) sold less than Organigram, about 2,600 kg. And yet, prior to announcing its intent to uplist, Organigram’s market cap was $991.5 million – less than 6% of Canopy’s and half of Aphria’s.
That’s why it’s so important to buy before the announcement. Clearly, the market is not pricing in the full potential here.
Net sales for the latest quarter grew by 219% over the prior year, and an even more impressive, 287% from the prior quarter. Management expects sales will more than double again in the current quarter.
This is a real company with real potential. That potential is multiplied by the tailwind of jumping to the NASDAQ. This is not some publicity stunt. First of all, companies have to meet stringent requirements to be approved for trading. And second, one of my team members has followed this company for years and has spoken with the CEO, Greg Engel, who used to be the head of Tilray.
My team member was clearly impressed with Engle’s knowledge and insight into the industry, but he was also impressed that Engle didn’t seem interested in making a big splash with press releases. He appears to be more focused on building a strong and lasting company – uplisting to the NASDAQ certainly helps with that – and being well-positioned for the future. By the way, that includes cannabis edibles and beverages, both of which will become legal in Canada this fall.
We started with five Jumper Stock opportunities, two of which have already announced their intention to uplist. One is up 55% in less than three months, and now Organigram is next in line.
I believe so strongly in this opportunity that I want to share additional information with you that I usually would not give away. Organigram is actually trading right around my buy under limit, so there should still be time to get in. (If you want to know my buy limit, click here for more information on how you can join Early Stage Investor and receive immediate access to my Jumper Stocks and all of my recommendations.)
I’m also lining up more potential Jumper Stocks as we speak. As far as I know, our research firm is the only one to not only uncover but exploit this phenomenon. My system includes additional criteria above the standard U.S. listing requirements, and once they are met, they are a good signal that a cannabis company is about to make the jump. And when it does, watch out!
Jumper Stocks will remain one of the great cannabis investing opportunities for some time as more companies go public on smaller exchanges and legalization opens up the door for more to make the jump to the big exchanges.
Some day, most marijuana stocks will trade on the big exchanges. But that day is still years away, so now is the time to make big money in Jumper Stocks.
P.S. I’ve been in this business for nearly two decades and have never seen a method of quickly growing your wealth this promising.
You can make a heck of a lot of money investing in the best marijuana stocks BEFORE they get listed here in America… before they “jump.”
We’ve already gotten some great results from my Jumper Stock System, and this is just the beginning. As legalization gets closer, the trickle of companies uplisting to major exchanges could turn into a flood
If you’d like to see this approach in action, learn how it could make virtually anyone a millionaire and learn the name of one of my other Jumper Stocks, click here to watch this special presentation.
You’ll get the name of one of my Jumper Stocks for FREE… just for watching. You’ll also learn how to get access to additional stocks that could soar 1,000%. Go here to learn more.
Self-driving cars – aka “autonomous vehicles” (AVs) – represent one of the biggest investment opportunities of the next 25 years. This innovation will transform huge portions of our economy and create trillion dollar ripple effects through time. It will create huge new winners in short periods of time. It will demolish losers in equally short periods of time. It’s critical that you stay on the right side of this trend. Learn more here.
Marijuana has been outlawed most everywhere for decades… but now a wave of legalization is starting to sweep the world. This will create massive new markets and massive stock market winners. Learn more here.
If I had to make one bet for 2019 it would be that betting is going to be big. The Supreme Court’s May 14 ruling cleared the way for states to allow sports gambling. And in my 25 years of investing experience, I honestly cannot remember many things that come close to magnitude of the investing opportunity that opened up to us. Massive amounts of money are involved in sports betting, and I expect massive amounts of money will be made, too. Learn more here.
Don't miss out on the incredible megatrends that are shaping today's market. Gain access to the most powerful market insights and stock advice from Matt McCall absolutely FREE. Join Today!